Compare Oxford Lane Capital Corp (OXLC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Pfizer Inc — how do they compare? Oxford Lane Capital Corp trades at $8.59 (market cap $835.71M), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 189.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 49 Days and Pfizer Inc for 158 Days on average.
| OXLC | PFE | |
|---|---|---|
Market Cap | $835.71M | $158.56B |
Volume | 1,125,263 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $16.74 | $29.02 |
52-Week Low | $8.15 | $23.67 |
Typical Hold Time | 49 Days | 158 Days |
Enterprise Value | $1.23B | $210.06B |
Dividend Yield | 28.15% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook indicated by moving averages and oscillators. Recent earnings misses and a sharp decline in 2026 revenue and net income highlight fundamental challenges, though the stock trades below book value. The company maintains a regular dividend payout, but negative cash flow from operations and high interest expenses pose sustainability concerns.
The outlook is cautious due to deteriorating profitability and bearish sentiment, though deep valuation discounts may attract contrarian investors. Key risks include earnings volatility, dividend coverage, and market sentiment shifts. Analyst consensus is mixed, with half recommending buy but technicals signaling sell.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
